SAN JOSE, Calif., Sept. 23, 2024 /PRNewswire/ — AHEAD Medicine Corporation, a pioneering AI HealthTech company, is excited to announce a significant advancement in its flagship product, Cyto-Copilot. The new analysis module now supports AML versus non-neoplastic diagnostic classification across five different flow cytometry test panels and instrument models. This groundbreaking development will be presented at the upcoming European Society of Clinical Cytometry Analysis (ESCCA) 2024 and International Clinical Cytometry Society (ICCS) 2024 conferences under the title “Enhancing Accessibility and Reproducibility of Flow Cytometry Data Analysis with Panel-Agnostic Machine Learning-Based Automated Cross-Panel Classification for Acute Leukemia.”
Cyto-copilot is an advanced artificial intelligence (AI)-driven platform engineered to transform the analysis of complex clinical flow cytometry data. The platform integrates a suite of machine learning models and visualization tools to enable efficiency, consistent and scalable sample-level and cell-level classification, significantly reducing healthcare professional workload in the diagnostic process. Cyto-Copilot assists lab professionals in triaging cases through batch analysis, minimizes inconsistencies inherent in manual analysis, resulting in a more streamlined workflow and improved diagnostic accuracy – critical factors in enhancing patient outcomes and overall healthcare quality.
AHEAD is dedicated to develop AI-enabled clinical data analysis solutions and improving patient outcomes through innovation. The company continues to invest in research and development to expand the capabilities of Cyto-Copilot and explore new applications for its technology.
For further details about AHEAD Medicine, please visit https://www.aheadmedicine.com/
About AHEAD Medicine Corporation
AHEAD Medicine Corporation stands at the forefront of AI HealthTech innovation, specializing in advanced data analytics for disease diagnosis, post-treatment monitoring, biomedical research, and quality assurance in cell therapy manufacturing. With a focus on improving patient outcomes and enhancing clinical workflows, AHEAD is committed to advancing the future of healthcare.
SOURCE AHEAD Medicine Corporation
SEATTLE, Dec. 06, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage…
– Data support initiation of a combination cohort in the ongoing Phase 1 clinical trial…
SPRING, Texas, Dec. 06, 2025 (GLOBE NEWSWIRE) -- Io Therapeutics, Inc., a privately held pharmaceutical…
Ficerafusp alfa 750mg QW in combination with pembrolizumab demonstrates consistent overall response rate and safety…
TUS+VEN+AZA triplet frontline therapy demonstrates high rates of efficacy and MRD-negative remissions in newly diagnosed…
Demonstrated meaningful overall anemia responses across all patient subgroups, regardless of baseline transfusion status Anemia response…